Literature DB >> 8522680

Elimination of liposomal amphotericin by hemodiafiltration.

M Tomlin, G S Priestley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522680     DOI: 10.1007/bf01711556

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

1.  Liposomal amphotericin B and continuous venous-venous haemofiltration.

Authors:  H Humphreys; D A Oliver; R Winter; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

2.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Authors:  F Meunier; H G Prentice; O Ringdén
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

Review 3.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

4.  A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients.

Authors:  J Tollemar; S Andersson; O Ringdén; G Tydén
Journal:  Mycoses       Date:  1992 Sep-Oct       Impact factor: 4.377

  4 in total
  4 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

2.  [Not Available].

Authors:  M Tomlin; A Basarab; D Warnock
Journal:  Clin Drug Investig       Date:  1997       Impact factor: 2.859

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 4.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.